Onxeo - Progress with both REVOCAN and DRIIV-1b trials
Despite the restrictions caused by the ongoing COVID-19 pandemic, Onxeo has managed to initiate a new Phase Ib/II REVOCAN study in relapsed ovarian cancer, which evaluates AsiDNA’s potentially unique ability to reverse tumour resistance to the PARP inhibitor, niraparib. First data are expected in early 2021. Onxeo also reported updated results from the second cohort in the Phase Ib study with AsiDNA plus chemotherapy in various solid tumours. Onxeo’s second lead product from the platON platform has been successfully advancing through early preclinical development and could enter the clinic within the next 18–24 months. Our valuation is €160m or €2.04 per share.Onxeo is a clinical-stage biotechnology company specializing in the development of innovative drugs for the treatment of orphan diseases, in particular in oncology, driven by high therapeutic demand in one of the fastest growing segments of the pharmaceutical industry. Co.'s orphan oncology product portfolio comprises 3 products (Livatag®, Beleodaq®, and AsiDNA™), ranging from preclinical to advanced phases of clinical development.
Edison is an investment research and advisory company, with offices in North America, Europe, the Middle East and AsiaPac. The heart of Edison is our world renowned equity research platform and deep multi-sector expertise. At Edison Investment Research, our research is widely read by international investors, advisors and stakeholders. Edison Advisors leverages our core research platform to provide differentiated services including investor relations and strategic consulting.
.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.